Target intelligence / Profile preview

Vibrio cholerae O1 and O139 surface antigen

Molecular classification
Bacterial surface antigen, Polysaccharide antigen, Lipopolysaccharide (LPS) component, Other (not a protein, enzyme, receptor or transporter; rather a carbohydrate antigen found on Gram-negative bacteria)
01

Overview

The Vibrio cholerae O1 and O139 surface antigens are carbohydrate structures located on the outer membrane of the bacterium Vibrio cholerae, forming the O-antigenic portion of its lipopolysaccharide (LPS)[1][4]. These antigens define the two main epidemic serogroups, O1 and O139, that cause all global pandemics and large outbreaks of cholera, a severe diarrheal disease[1][6]. The O1 antigen is a homopolymer of perosamine sugars, while the O139 antigen is chemically distinct and also associated with a polysaccharide capsule[1][6]. They are essential virulence and immune determinants, required for colonization, immune evasion, and survival, and are principal targets for both natural immune responses and cholera vaccines[2][4]. Antigenic phase variation can modulate expression of these antigens, promoting bacterial persistence and occasionally reducing vaccine efficacy[2]. Both antigens are diagnostic and vaccine targets; antibodies elicited against them can provide strain-specific protection[2][4].

Other names
O1 antigenO139 antigenVibrio cholerae O1 surface antigenVibrio cholerae O139 surface antigenV. cholerae O1 LPS (lipopolysaccharide O1 antigen)V. cholerae O139 LPS (lipopolysaccharide O139 antigen)O-antigen (of V. cholerae)
02

Mechanism of action

Induction of adaptive immune response (production of O1/O139-specific antibodies to neutralize and clear V. cholerae); Inhibition of colonization and infection by blocking antigen attachment to host tissues; Bacteriophage therapy (some phages specifically target O1 antigen for attachment and lysis)

03

Biological functions

Immune response activation (major target for the host immune system)Phage receptor (target for bacteriophage attachment and lysis)Virulence determinant (essential for infectivity and epidemic potential)Vaccine antigen (key antigen for cholera vaccine development)Biofilm formation and environmental persistence (contributes indirectly via LPS interactions)
04

Disease associations

Infection (primary causal antigen for cholera)Other (epidemic spread, immune evasion, environmental persistence)
05

Safety considerations

Antigenic variation (phase variation/mutation can reduce vaccine efficacy and promote immune escape)Limited cross-protection (immunity against O1 does not protect from O139 and vice versa; non-O1/non-O139 strains also exist)Reactogenicity of vaccine candidates (may provoke immune side effects)Diagnostic specificity (antibodies must reliably distinguish between serogroups and not cross-react with non-cholera Vibrios)
06

Interacting drugs

Oral cholera vaccines (inactivated or subunit vaccines containing O1 and/or O139 surface antigens)

1 more in the full profile.

07

Biomarkers

O1 antigen (serological marker for O1 V. cholerae infection and vaccine response)O139 antigen (serological marker for O139 strain infection and vaccine response)

Beyond the preview

Go deeper on Vibrio cholerae O1 and O139 surface antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vibrio cholerae O1 and O139 surface antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call